x
|
Quarterly
Report Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of
1934 for the Quarter Ended June 30,
2007
|
o
|
Transition
Report Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of
1934
|
Delaware
|
04-2209186
|
(State
of incorporation or organization)
|
(I.R.S.
Employer Identification No.)
|
|
|
81
Wyman Street, P.O. Box 9046
|
|
Waltham,
Massachusetts
|
02454-9046
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Class
|
|
Outstanding
at June 30, 2007
|
||
Common
Stock, $1.00 par value
|
|
426,580,049
|
June
30,
|
December
31,
|
||||||
(In
millions)
|
2007
|
2006
|
|||||
(Unaudited)
|
|||||||
Current
Assets:
|
|||||||
Cash
and cash
equivalents
|
$
|
951.2
|
$
|
667.4
|
|||
Short-term investments, at quoted market value (amortized cost
of $25.7
and $23.8)
|
22.7
|
23.8
|
|||||
Accounts
receivable, less allowances of $49.8 and $45.0
|
1,422.5
|
1,392.7
|
|||||
Inventories:
|
|||||||
Raw
materials
|
318.8
|
307.7
|
|||||
Work
in process
|
132.6
|
121.7
|
|||||
Finished
goods
|
731.8
|
735.1
|
|||||
Deferred
tax assets
|
194.5
|
209.2
|
|||||
Other
current assets
|
233.0
|
201.9
|
|||||
4,007.1
|
3,659.5
|
||||||
Property,
Plant and Equipment, at Cost
|
1,585.4
|
1,533.0
|
|||||
Less:
Accumulated depreciation and amortization
|
356.9
|
276.3
|
|||||
1,228.5
|
1,256.7
|
||||||
Acquisition-related Intangible Assets, net of Accumulated Amortization
of
$577.1 and $276.4
|
7,208.0
|
7,511.6
|
|||||
Other
Assets
|
276.9
|
309.4
|
|||||
Goodwill
|
8,551.6
|
8,525.0
|
|||||
$
|
21,272.1
|
$
|
21,262.2
|
June
30,
|
December
31,
|
||||||
(In
millions except share amounts)
|
2007
|
2006
|
|||||
(Unaudited)
|
|||||||
Current
Liabilities:
|
|||||||
Short-term obligations and current maturities of long-term
obligations
|
$
|
24.8
|
$
|
483.3
|
|||
Accounts
payable
|
622.3
|
630.8
|
|||||
Accrued
payroll and employee benefits
|
215.7
|
253.3
|
|||||
Accrued
income taxes
|
66.1
|
60.3
|
|||||
Deferred
revenue
|
139.9
|
121.3
|
|||||
Other
accrued expenses (Notes 2, 10 and 11)
|
534.2
|
603.3
|
|||||
1,603.0
|
2,152.3
|
||||||
Deferred
Income Taxes
|
2,445.4
|
2,557.5
|
|||||
Other
Long-term Liabilities
|
514.2
|
459.9
|
|||||
Long-term
Obligations (Note 9)
|
2,177.7
|
2,180.7
|
|||||
Shareholders’
Equity:
|
|||||||
Preferred
stock, $100 par value, 50,000 shares authorized; none
issued
|
|||||||
Common
stock, $1 par value, 1,200,000,000 shares authorized; 434,228,110
and
424,240,292 shares issued
|
434.2
|
424.2
|
|||||
Capital in excess of par value
|
12,056.2
|
11,810.4
|
|||||
Retained earnings
|
2,076.2
|
1,773.4
|
|||||
Treasury stock at cost, 7,648,061 and 7,635,184 shares
|
(254.5
|
)
|
(246.4
|
)
|
|||
Accumulated other comprehensive items (Note 6)
|
219.7
|
150.2
|
|||||
14,531.8
|
13,911.8
|
||||||
$
|
21,272.1
|
$
|
21,262.2
|
Three
Months Ended
|
|||||||
June
30,
|
July
1,
|
||||||
(In
millions except per share amounts)
|
2007
|
2006
|
|||||
Revenues
|
$
|
2,385.9
|
$
|
713.5
|
|||
Costs
and Operating Expenses:
|
|||||||
Cost
of revenues
|
1,449.3
|
388.9
|
|||||
Selling,
general and administrative expenses
|
626.6
|
206.9
|
|||||
Research
and development expenses
|
58.7
|
40.7
|
|||||
Restructuring
and other costs, net (Note 11)
|
8.3
|
4.8
|
|||||
2,142.9
|
641.3
|
||||||
Operating
Income
|
243.0
|
72.2
|
|||||
Other
Expense, Net (Note 4)
|
(20.7
|
)
|
(3.4
|
)
|
|||
Income
from Continuing Operations Before Provision for Income Taxes
|
222.3
|
68.8
|
|||||
Provision
for Income Taxes
|
(34.4
|
)
|
(19.8
|
)
|
|||
Income
from Continuing Operations
|
187.9
|
49.0
|
|||||
Loss on Disposal of Discontinued Operations (includes income tax
provision
of $1.8 in 2007 and income tax benefit of $0.6 in 2006; Note
14)
|
(24.0
|
)
|
(1.1
|
)
|
|||
Net
Income
|
$
|
163.9
|
$
|
47.9
|
|||
Earnings
per Share from Continuing Operations (Note 5):
|
|||||||
Basic
|
$
|
.44
|
$
|
.30
|
|||
Diluted
|
$
|
.42
|
$
|
.30
|
|||
Earnings
per Share (Note 5):
|
|||||||
Basic
|
$
|
.39
|
$
|
.30
|
|||
Diluted
|
$
|
.37
|
$
|
.29
|
|||
Weighted
Average Shares (Note 5):
|
|||||||
Basic
|
424.0
|
161.3
|
|||||
Diluted
|
446.5
|
165.5
|
Six
Months Ended
|
|||||||
June
30,
|
July
1,
|
||||||
(In
millions except per share amounts)
|
2007
|
2006
|
|||||
Revenues
|
$
|
4,724.1
|
$
|
1,397.8
|
|||
Costs
and Operating Expenses:
|
|||||||
Cost
of revenues
|
2,907.6
|
760.6
|
|||||
Selling,
general and administrative expenses
|
1,246.9
|
409.4
|
|||||
Research
and development expenses
|
118.5
|
79.4
|
|||||
Restructuring
and other costs, net (Note 11)
|
15.7
|
8.4
|
|||||
4,288.7
|
1,257.8
|
||||||
Operating
Income
|
435.4
|
140.0
|
|||||
Other
Expense, Net (Note 4)
|
(47.4
|
)
|
(7.1
|
)
|
|||
Income
from Continuing Operations Before Provision for Income Taxes
|
388.0
|
132.9
|
|||||
Provision
for Income Taxes
|
(61.3
|
)
|
(40.3
|
)
|
|||
Income
from Continuing Operations
|
326.7
|
92.6
|
|||||
Income
from Discontinued Operations (net of income tax provision of $0.1
in 2007;
Note 14)
|
0.1
|
—
|
|||||
(Loss) Gain on Disposal of Discontinued Operations (includes income
tax
provision of $1.8 and
$1.3; Note 14)
|
(24.0
|
)
|
2.2
|
||||
Net
Income
|
$
|
302.8
|
$
|
94.8
|
|||
Earnings
per Share from Continuing Operations (Note 5):
|
|||||||
Basic
|
$
|
.77
|
$
|
.57
|
|||
Diluted
|
$
|
.74
|
$
|
.56
|
|||
Earnings
per Share (Note 5):
|
|||||||
Basic
|
$
|
.72
|
$
|
.58
|
|||
Diluted
|
$
|
.68
|
$
|
.57
|
|||
Weighted
Average Shares (Note 5):
|
|||||||
Basic
|
422.0
|
162.2
|
|||||
Diluted
|
443.8
|
166.3
|
Six
Months Ended
|
|||||||
June
30,
|
July
1,
|
||||||
(In
millions)
|
2007
|
2006
|
|||||
Operating
Activities:
|
|||||||
Net
income
|
$
|
302.8
|
$
|
94.8
|
|||
Income
from discontinued operations
|
(0.1
|
)
|
—
|
||||
Loss
(Gain) on disposal of discontinued operations
|
24.0
|
(2.2
|
)
|
||||
Income
from continuing operations
|
326.7
|
92.6
|
|||||
Adjustments to reconcile income from continuing operations to net
cash
provided by
operating
activities:
|
|||||||
Depreciation
and amortization
|
372.4
|
76.4
|
|||||
Change
in deferred income taxes
|
(10.3
|
)
|
(10.7
|
)
|
|||
Noncash
equity compensation
|
26.1
|
13.0
|
|||||
Noncash charges for sale of inventories revalued at the
date of
acquisition
|
47.6
|
—
|
|||||
Other
noncash expenses, net
|
18.8
|
0.2
|
|||||
Changes in current accounts, excluding the effects of acquisitions
and
dispositions:
|
|||||||
Accounts receivable
|
(41.7
|
)
|
36.6
|
||||
Inventories
|
(57.8
|
)
|
(28.4
|
)
|
|||
Other current assets
|
(25.6
|
)
|
(3.8
|
)
|
|||
Accounts payable
|
(17.2
|
)
|
(11.7
|
)
|
|||
Other current liabilities
|
(82.6
|
)
|
(64.5
|
)
|
|||
Net
cash provided
by continuing operations
|
556.4
|
99.7
|
|||||
Net
cash used in
discontinued operations
|
(2.3
|
)
|
(1.5
|
)
|
|||
Net
cash provided by
operating activities
|
554.1
|
98.2
|
|||||
Investing
Activities:
|
|||||||
Acquisitions,
net of cash acquired
|
(39.1
|
)
|
(26.6
|
)
|
|||
Refund
of acquisition purchase price
|
4.6
|
—
|
|||||
Proceeds
from sale of available-for-sale investments
|
1.7
|
151.0
|
|||||
Purchases
of available-for-sale investments
|
(1.8
|
)
|
(77.9
|
)
|
|||
Purchases
of property, plant and equipment
|
(71.8
|
)
|
(21.8
|
)
|
|||
Proceeds
from sale of property, plant and equipment
|
14.1
|
2.1
|
|||||
Proceeds
from sale of product lines
|
—
|
8.9
|
|||||
Collection
of notes receivable
|
48.2
|
2.8
|
|||||
Increase
in other assets
|
(18.3
|
)
|
(8.1
|
)
|
|||
Net cash (used in) provided by continuing operations
|
(62.4
|
)
|
30.4
|
||||
Net cash provided by discontinued operations
|
28.8
|
5.3
|
|||||
Net cash (used in) provided by investing activities
|
$
|
(33.6
|
)
|
$
|
35.7
|
Six
Months Ended
|
|||||||
June
30,
|
July
1,
|
||||||
(In
millions)
|
2007
|
2006
|
|||||
Financing
Activities:
|
|||||||
(Decrease)
increase in short-term notes payable
|
$
|
(452.5
|
)
|
$
|
36.6
|
||
Purchases
of company common stock
|
—
|
(228.0
|
)
|
||||
Net
proceeds from issuance of company common stock
|
223.6
|
22.1
|
|||||
Tax
benefits from exercised stock options
|
17.0
|
5.6
|
|||||
Redemption
and repayment of long-term obligations
|
(8.7
|
)
|
—
|
||||
Net cash used in financing activities
|
(220.6
|
)
|
(163.7
|
)
|
|||
Exchange
Rate Effect on Cash of Continuing Operations
|
(16.1
|
)
|
5.2
|
||||
Increase
(Decrease) in Cash and Cash Equivalents
|
283.8
|
(24.6
|
)
|
||||
Cash
and Cash Equivalents at Beginning of Period
|
667.4
|
214.3
|
|||||
Cash
and Cash Equivalents at End of Period
|
$
|
951.2
|
$
|
189.7
|
|||
Supplemental
Cash Flow Information:
|
|||||||
Fair
value of assets of acquired businesses
|
$
|
39.8
|
$
|
36.1
|
|||
Cash
paid for acquired businesses
|
(30.8
|
)
|
(26.6
|
)
|
|||
Liabilities
assumed of acquired businesses
|
$
|
9.0
|
$
|
9.5
|
|||
Conversion
of subordinated convertible debentures
|
$
|
0.4
|
$
|
—
|
|||
Issuance
of restricted stock
|
$
|
11.9
|
$
|
0.9
|
1.
|
General
|
2.
|
Acquisitions
|
2.
|
Acquisitions
(continued)
|
(In
millions)
|
Spectronex/Flux
|
Other
|
Total
|
|||||||
Purchase
Price:
|
||||||||||
Cash
paid (a)
|
$
|
25.8
|
$
|
6.8
|
$
|
32.6
|
||||
Cash
acquired
|
(1.8
|
)
|
—
|
(1.8
|
)
|
|||||
$
|
24.0
|
$
|
6.8
|
$
|
30.8
|
|||||
Allocation:
|
||||||||||
Current
assets
|
$
|
8.1
|
$
|
1.8
|
$
|
9.9
|
||||
Property,
plant and equipment
|
0.4
|
0.3
|
0.7
|
|||||||
Acquired
intangible assets
|
14.8
|
3.4
|
18.2
|
|||||||
Goodwill
|
9.1
|
1.9
|
11.0
|
|||||||
Liabilities
assumed
|
(8.4
|
)
|
(0.6
|
)
|
(9.0
|
)
|
||||
$
|
24.0
|
$
|
6.8
|
$
|
30.8
|
(a)
|
Includes
transaction costs.
|
(In
millions)
|
Spectronex/Flux
|
Other
|
Total
|
|||||||
Customer
Relationships
|
$
|
12.9
|
$
|
1.5
|
$
|
14.4
|
||||
Product
Technology
|
1.5
|
1.9
|
3.4
|
|||||||
Tradenames
|
0.4
|
—
|
0.4
|
|||||||
$
|
14.8
|
$
|
3.4
|
$
|
18.2
|
2.
|
Acquisitions
(continued)
|
(In
millions)
|
Fisher
|
Cohesive
|
|||||
Fair
Value of Common Stock Issued to Fisher Shareholders
|
$
|
9,777.8
|
$
|
—
|
|||
Fair Value of Fisher Stock Options and Warrants Converted into
Options in
Company Common Stock
|
502.3
|
—
|
|||||
Debt
Assumed
|
2,284.7
|
—
|
|||||
Cash
Paid Including Transaction Costs
|
39.0
|
71.3
|
|||||
Cash
Acquired
|
(392.0
|
)
|
(0.3
|
)
|
|||
$
|
12,211.8
|
$
|
71.0
|
||||
Allocation:
|
|||||||
Current
assets
|
$
|
1,914.3
|
$
|
5.6
|
|||
Property,
plant and equipment
|
944.8
|
1.0
|
|||||
Acquired
intangible assets
|
7,082.0
|
37.0
|
|||||
Goodwill
|
6,552.4
|
32.9
|
|||||
Other
assets
|
333.2
|
—
|
|||||
Liabilities
assumed
|
(4,068.1
|
)
|
(5.5
|
)
|
|||
Fair
value of convertible debt allocable to equity
|
(546.8
|
)
|
—
|
||||
$
|
12,211.8
|
$
|
71.0
|
(In
millions)
|
Fisher
|
Cohesive
|
|||||
Indefinite
Lives:
|
|||||||
Trademarks
|
$
|
1,326.9
|
$
|
—
|
|||
Definite
Lives:
|
|||||||
Customer
relationships
|
4,275.3
|
19.0
|
|||||
Product
technology
|
844.8
|
14.6
|
|||||
Tradenames
|
635.0
|
3.4
|
|||||
$
|
7,082.0
|
$
|
37.0
|
2.
|
Acquisitions
(continued)
|
Three
Months Ended
|
Six
Months Ended
|
||||||
(In
millions except per share amounts)
|
July
1, 2006 (a)
|
July
1, 2006 (b)
|
Revenues
|
$
|
2,188.7
|
$
|
4,285.1
|
|||
Net
Income
|
$
|
99.4
|
$
|
93.1
|
|||
Earnings per Share from Continuing Operations:
|
|||||||
Basic
|
$
|
.24
|
$
|
.22
|
|||
Diluted
|
$
|
.23
|
$
|
.21
|
|||
Earnings
Per Share:
|
|||||||
Basic
|
$
|
.24
|
$
|
.23
|
|||
Diluted
|
$
|
.23
|
$
|
.22
|
(a)
|
Includes
$17 million pre-tax charge to cost of revenues for sale of Fisher
inventories revalued at the date of
merger.
|
(b)
|
Includes
$114 million pre-tax charge to cost of revenues for the sale of
Fisher
inventories revalued at the date of merger, $15 million pre-tax
charge for
Fisher’s in-process research and development and $37 million pre-tax
charge for accelerated vesting of equity-based awards resulting
from the
change in control occurring at the date of the Fisher
merger.
|
(In
millions)
|
Severance
|
Abandonment
of
Excess
Facilities
|
Other
|
Total
|
||||||||||||||
Balance
at December 31, 2006
|
$
|
26.0
|
$
|
3.1
|
$
|
1.3
|
$ |
30.4
|
||||||||||
Reserves
established
|
9.7
|
3.7
|
2.0
|
15.4
|
||||||||||||||
Payments
|
(24.1
|
)
|
(0.2
|
)
|
(0.5
|
)
|
(24.8
|
)
|
||||||||||
Decrease recorded as a reduction in goodwill
|
(0.1
|
)
|
(0.5
|
)
|
—
|
(0.6
|
) | |||||||||||
Currency
translation
|
0.1
|
—
|
—
|
0.1
|
||||||||||||||
Balance
at June 30, 2007
|
$
|
11.6
|
$
|
6.1
|
$
|
2.8
|
$ |
20.5
|
(In
millions)
|
Severance
|
Abandonment
of
Excess
Facilities
|
Other
|
Total
|
|||||||||||||
Balance
at December 31, 2006
|
$
|
2.2
|
$
|
2.7
|
$
|
0.1
|
$
|
$5.0
|
|||||||||
Payments
|
(1.6
|
)
|
(0.6
|
)
|
—
|
(2.2
|
)
|
||||||||||
Decrease recorded as a reduction in goodwill
|
(0.2
|
)
|
—
|
—
|
(0.2
|
)
|
|||||||||||
Balance
at June 30, 2007
|
$
|
0.4
|
$
|
2.1
|
$
|
0.1
|
$
|
$2.6
|
3.
|
Business
Segment Information
|
Three
Months Ended
|
Six
Months Ended
|
||||||||||||
June
30,
|
July
1,
|
June
30,
|
July
1,
|
||||||||||
(In
millions)
|
2007
|
2006
|
2007
|
2006
|
Revenues:
|
|||||||||||||
Analytical
Technologies
|
$
|
1,038.5
|
$
|
531.5
|
$
|
2,044.7
|
$
|
1,036.1
|
|||||
Laboratory
Products and Services
|
1,433.7
|
182.0
|
2,850.2
|
361.7
|
|||||||||
Eliminations
|
(86.3
|
)
|
—
|
(170.8
|
)
|
—
|
|||||||
Consolidated
revenues
|
$
|
2,385.9
|
$
|
713.5
|
$
|
4,724.1
|
$
|
1,397.8
|
|||||
Operating
Income:
|
|||||||||||||
Analytical
Technologies (a)
|
$
|
205.7
|
$
|
77.5
|
$
|
395.5
|
$
|
149.0
|
|||||
Laboratory
Products and Services (a)
|
198.9
|
26.4
|
384.6
|
51.9
|
|||||||||
Subtotal
reportable segments (a)
|
404.6
|
103.9
|
780.1
|
200.9
|
|||||||||
Cost
of revenues charges
|
(11.2
|
)
|
(1.3
|
)
|
(47.6
|
)
|
(1.3
|
)
|
|||||
Restructuring
and other costs, net
|
(8.3
|
)
|
(4.8
|
)
|
(15.7
|
)
|
(8.4
|
)
|
|||||
Amortization of acquisition-related intangible assets
|
(142.1
|
)
|
(25.6
|
)
|
(281.4
|
)
|
(51.2
|
)
|
|||||
Consolidated
operating income
|
243.0
|
72.2
|
435.4
|
140.0
|
|||||||||
Other
expense, net (b)
|
(20.7
|
)
|
(3.4
|
)
|
(47.4
|
)
|
(7.1
|
)
|
|||||
Income from continuing operations before provision for
income taxes
|
$
|
222.3
|
$
|
68.8
|
$
|
388.0
|
$
|
132.9
|
|||||
Equity-based
Compensation Expense:
|
|||||||||||||
Analytical
Technologies
|
$
|
5.7
|
$
|
5.1
|
$
|
12.2
|
$
|
9.7
|
|||||
Laboratory
Products and Services
|
6.6
|
1.8
|
13.9
|
3.3
|
|||||||||
Consolidated equity-based compensation expense
|
$
|
12.3
|
$
|
6.9
|
$
|
26.1
|
$
|
13.0
|
|||||
Amortization:
|
|||||||||||||
Analytical
Technologies
|
$
|
56.7
|
$
|
6.5
|
$
|
109.3
|
$
|
13.0
|
|||||
Laboratory
Products and Services
|
85.4
|
19.1
|
172.1
|
38.2
|
|||||||||
Consolidated
amortization
|
$
|
142.1
|
$
|
25.6
|
$
|
281.4
|
$
|
51.2
|
|||||
Depreciation:
|
|||||||||||||
Analytical
Technologies
|
$
|
20.4
|
$
|
7.5
|
$
|
40.8
|
$
|
14.7
|
|||||
Laboratory
Products and Services
|
24.6
|
5.9
|
50.2
|
10.5
|
|||||||||
Consolidated
depreciation
|
$
|
45.0
|
$
|
13.4
|
$
|
91.0
|
$
|
25.2
|
(a)
|
Represents
operating income before certain charges to cost of revenues; restructuring
and other costs, net and amortization of acquisition-related
intangibles.
|
(b)
|
The
company does not allocate other income and expenses to its segments.
|
4.
|
Other
Expense, Net
|
Three
Months Ended
|
Six
Months Ended
|
||||||||||||
June
30,
|
July
1,
|
June
30,
|
July
1,
|
||||||||||
(In
millions)
|
2007
|
2006
|
2007
|
2006
|
|||||||||
Interest
Income
|
$
|
10.6
|
$
|
3.4
|
$
|
19.5
|
$
|
6.9
|
|||||
Interest
Expense
|
(33.2
|
)
|
(8.0
|
)
|
(70.4
|
)
|
(15.7
|
)
|
|||||
Other
Items, Net
|
1.9
|
1.2
|
3.5
|
1.7
|
|||||||||
$
|
(20.7
|
)
|
$
|
(3.4
|
)
|
$
|
(47.4
|
)
|
$
|
(7.1
|
)
|
5.
|
Earnings
per Share
|
Three
Months Ended
|
Six
Months Ended
|
||||||||||||
June 30, | July 1, | June 30, | July 1, | ||||||||||
(In millions) | 2007 | 2006 | 2007 | 2006 | |||||||||
Income from Continuing Operations
|
$
|
187.9
|
$
|
49.0
|
$
|
326.7
|
$
|
92.6
|
|||||
Income from Discontinued Operations
|
—
|
—
|
0.1
|
—
|
|||||||||
(Loss) Gain on Disposal of Discontinued Operations
|
(24.0
|
)
|
(1.1
|
) |
(24.0
|
)
|
2.2
|
||||||
Net Income for Basic Earnings per Share
|
163.9
|
47.9
|
302.8
|
94.8
|
|||||||||
Effect
of Convertible Debentures
|
—
|
0.4
|
—
|
0.8
|
|||||||||
Income
Available to Common Shareholders, as Adjusted for Diluted Earnings
per
Share
|
$
|
163.9
|
$
|
48.3
|
$
|
302.8
|
$
|
95.6
|
|||||
Basic
Weighted Average Shares
|
424.0
|
161.3
|
422.0
|
162.2
|
|||||||||
Effect
of:
|
|||||||||||||
Convertible
debentures
|
13.7
|
1.8
|
12.7
|
1.8
|
|||||||||
Stock options, restricted stock awards and warrants
|
8.8
|
2.4
|
9.1
|
2.3
|
|||||||||
Diluted Weighted Average Shares
|
446.5
|
165.5
|
443.8
|
166.3
|
|||||||||
Basic
Earnings per Share:
|
|||||||||||||
Continuing operations
|
$
|
.44
|
$
|
.30
|
$
|
.77
|
$
|
.57
|
|||||
Discontinued
operations
|
(.06
|
)
|
(.01
|
) |
(.06
|
)
|
.01
|
||||||
$
|
.39
|
$
|
.30
|
$
|
.72
|
$
|
.58
|
||||||
Diluted
Earnings per Share:
|
|||||||||||||
Continuing operations
|
$
|
.42
|
$
|
.30
|
$
|
.74
|
$
|
.56
|
|||||
Discontinued
operations
|
(.05
|
)
|
(.01
|
) |
(.05
|
)
|
.01
|
||||||
$
|
.37
|
$
|
.29
|
$
|
.68
|
$
|
.57
|
6.
|
Comprehensive
Income
|
7.
|
Equity-based
Compensation Expense
|
Three
Months Ended
|
Six
Months Ended
|
||||||||||||
June
30,
|
July
1,
|
June
30,
|
July
1,
|
||||||||||
(In millions) |
2007
|
2006
|
|
2007
|
2006
|
||||||||
|
|||||||||||||
Stock
Option Awards
|
$
|
8.3
|
$
|
6.4
|
$
|
17.6
|
$
|
11.8
|
|||||
Restricted
Share/Unit Awards
|
4.0
|
0.5
|
8.5
|
1.2
|
|||||||||
Total
Equity-based Compensation Expense
|
$
|
12.3
|
$
|
6.9
|
$
|
26.1
|
$
|
13.0
|
Equity-based
compensation expense is included in the accompanying statement
of income
as follows:
|
Three
Months Ended
|
Six
Months Ended
|
||||||||||||
June
30,
|
July
1,
|
June
30,
|
July
1,
|
||||||||||
(In millions) |
2007
|
2006
|
2007
|
2006
|
|||||||||
|
|||||||||||||
Cost
of Revenues
|
$
|
0.8
|
$
|
0.7
|
$
|
2.1
|
$
|
1.3
|
|||||
Selling,
General and Administrative Expenses
|
10.9
|
5.8
|
22.9
|
11.0
|
|||||||||
Research
and Development Expenses
|
0.6
|
0.4
|
1.1
|
0.7
|
|||||||||
Total
Equity-based Compensation Expense
|
$
|
12.3
|
$
|
6.9
|
$
|
26.1
|
$
|
13.0
|
8.
|
Defined
Benefit Pension Plans
|
Three
Months Ended
|
Six
Months Ended
|
||||||||||||
June
30,
|
July
1,
|
June
30,
|
July
1,
|
||||||||||
(In
millions)
|
2007
|
2006
|
2007
|
2006
|
|||||||||
Service
Cost
|
$
|
4.1
|
$
|
1.5
|
$
|
8.2
|
$
|
2.9
|
|||||
Interest
Cost on Benefit Obligation
|
14.0
|
3.7
|
27.9
|
7.2
|
|||||||||
Expected
Return on Plan Assets
|
(14.7
|
)
|
(3.0
|
)
|
(29.3
|
)
|
(6.0
|
)
|
|||||
Amortization
of Net Loss
|
0.9
|
0.9
|
1.8
|
1.8
|
|||||||||
Amortization
of Prior Service Costs
|
—
|
—
|
—
|
0.1
|
|||||||||
Net
Periodic Benefit Cost
|
$
|
4.3
|
$
|
3.1
|
$
|
8.6
|
$
|
6.0
|
Three
Months Ended
|
Six
Months Ended
|
||||||
(In
millions)
|
June
30, 2007
|
June
30, 2007
|
Service
Cost
|
$
|
0.2
|
$
|
0.4
|
|||
Interest
Cost on Benefit Obligation
|
0.4
|
0.8
|
|||||
Net
Periodic Benefit Cost
|
$
|
0.6
|
$
|
1.2
|
9.
|
Swap
Arrangement
|
10.
|
Warranty
Obligations
|
Six
Months Ended
|
|||||||
June
30,
|
July
1,
|
||||||
(In
millions)
|
2007
|
2006
|
|||||
Beginning
Balance
|
$
|
45.5
|
$
|
33.4
|
|||
Provision
charged to income
|
21.8
|
21.2
|
|||||
Usage
|
(18.8
|
)
|
(18.2
|
)
|
|||
Acquisitions
|
0.6
|
—
|
|||||
Adjustments
to previously provided warranties, net
|
—
|
(1.2
|
)
|
||||
Other,
net (a)
|
1.1
|
1.1
|
|||||
Ending
Balance
|
$
|
50.2
|
$
|
36.3
|
(a)
|
Primarily
represents the effects of currency
translation.
|
11.
|
Restructuring
and Other Costs, Net
|
(In millions)
|
Analytical
Technologies
|
Laboratory
Products
and
Services
|
Corporate
|
Total
|
|||||||||
Cost of Revenues
|
$
|
11.2
|
$
|
—
|
$
|
—
|
$
|
11.2
|
|||||
Restructuring
and Other Costs, Net
|
4.9
|
0.7
|
2.7
|
8.3
|
|||||||||
$
|
16.1
|
$
|
0.7
|
$
|
2.7
|
$
|
19.5
|
11.
|
Restructuring
and Other Costs, Net
(continued)
|
(In millions)
|
Analytical
Technologies
|
Laboratory
Products
and
Services
|
Corporate
|
Total
|
|||||||||
Cost of Revenues
|
$
|
40.3
|
$
|
7.3
|
$
|
—
|
$
|
47.6
|
|||||
Restructuring
and Other Costs, Net
|
8.0
|
1.3
|
6.4
|
15.7
|
|||||||||